Medical Equipment

PD-L1 And PIK3CA Testing Market Developments And Opportunities Across 2026–2030

April 15, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Large Will The PD-L1 And PIK3CA Testing Market Be By 2030 Compared To Its 2026 Market Size?

The pd-l1 and pik3ca testing market has shown rapid expansion in recent years. It is anticipated to increase from $1.67 billion in 2025 to $1.93 billion in 2026, at a compound annual growth rate (CAGR) of 15.5%. The historical growth of this market can be attributed to several factors, including the development of pd-l1 and pik3ca assays, their adoption in clinical trials, the growing prevalence of cancer, advancements in molecular diagnostics, and an increased awareness of personalized therapy.

The market for pd-l1 and pik3ca testing is projected to experience substantial expansion in the coming years. This market is anticipated to reach $3.4 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 15.2%. Factors contributing to this growth during the forecast period include the incorporation of AI in biomarker identification, the increasing use of liquid biopsy applications, the broader scope of precision oncology, collaborations between diagnostic and pharmaceutical firms, and the regulatory clearance of next-generation assays. Key developments expected in this period encompass targeted cancer biomarker screening, AI-powered mutation analysis, wider acceptance of liquid biopsy, synergy with drug development processes, and advanced high-throughput genomic screening.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/pd-l1-and-pik3ca-testing-global-market-report

Which Primary Drivers Are Impacting The PD-L1 And PIK3CA Testing Market Growth?

The rising incidence of cancer is projected to drive the growth of the PD-L1 and PIK3CA testing market in the future. Cancer is a condition marked by the uncontrolled multiplication and spread of abnormal cells within the body, capable of invading surrounding tissues and potentially spreading to other parts. The prevalence of cancer is attributable to increasing lifestyle-related risks and an aging population, which are leading to higher rates of diagnosis and a greater demand for early detection and effective treatment solutions. PD-L1 and PIK3CA testing support cancer management by facilitating accurate diagnoses and guiding targeted medicines, which helps tailor treatment regimens to individual patients and improve clinical outcomes. For instance, in September 2024, the American Cancer Society, a US-based non-profit organization, stated that global cancer cases in men are expected to increase by 84% by 2029, growing from 10.3 million in 2022 to 19 million. Therefore, the increasing prevalence of cancer is fueling the expansion of the PD-L1 and PIK3CA testing market.

How Is Segmentation Applied In The PD-L1 And PIK3CA Testing Market Segment Analysis?

The pd-l1 and pik3ca testing market covered in this report is segmented –

1) By Test Type: Immunohistochemistry, Next-Generation Sequencing, Polymerase Chain Reaction

2) By Sample Type: Tissue Samples, Liquid Biopsy Samples

3) By Applications: Cancer Diagnosis, Drug Development, Research, Other Applications

4) By End User: Hospitals And Clinics, Laboratories, Pharmaceutical Companies

Subsegments:

1) By Immunohistochemistry: Tissue Staining, Protein Expression Analysis

2) By Next-Generation Sequencing: Whole Genome Sequencing, Targeted Gene Sequencing, Exome Sequencing, Ribonucleic Acid (RNA) Sequencing

3) By Polymerase Chain Reaction: Quantitative Polymerase Chain Reaction, Digital Polymerase Chain Reaction

Which Trends Are Shaping Growth In The PD-L1 And PIK3CA Testing Market?

Leading companies operating within the PD-L1 and PIK3CA testing market are prioritizing technological advancements, including companion diagnostic integration, to enhance therapeutic targeting, improve treatment efficacy, and support personalized medicine approaches in oncology. Companion diagnostic integration refers to advanced, technology-driven testing frameworks developed in conjunction with specific targeted medicines to identify patient groups most likely to gain from particular treatments based on their biomarker profiles. For example, in October 2024, F. Hoffmann-La Roche AG, a Switzerland-based biotechnology and pharmaceutical company, launched Itovebi (inavolisib) in combination with palbociclib and fulvestrant for adults diagnosed with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative advanced or metastatic breast cancer. The Food and Drug Administration (FDA), a US-based federal agency, granted approval for this regimen, based on the pivotal Phase III INAVO120 study, which showed more than double the progression-free survival when compared to palbociclib and fulvestrant alone. This represents Roche’s first targeted therapy for HR-positive disease and incorporates a companion diagnostic to pinpoint eligible patients, signifying a major breakthrough in precision medicine for a patient population with limited initial treatment alternatives.

Who Are The Companies Participating In The PD-L1 And PIK3CA Testing Market Environment?

Major companies operating in the pd-l1 and pik3ca testing market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Laboratory Corporation of America Holdings (Labcorp), Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., Sonic Healthcare Limited, Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Myriad Genetics Inc., NeoGenomics Laboratories Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Caris Life Sciences, Foundation Medicine Inc., Amoy Diagnostics Co. Ltd., ACCB Biotech Private Limited, EntroGen Inc.

Get The Full PD-L1 And PIK3CA Testing Market Report:

https://www.thebusinessresearchcompany.com/report/pd-l1-and-pik3ca-testing-global-market-report

Where Is The PD-L1 And PIK3CA Testing Market Primarily Concentrated By Region?

North America was the largest region in the PD-L1 and PIK3CA testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pd-l1 and pik3ca testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized PD-L1 And PIK3CA Testing Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/pd-l1-and-pik3ca-testing-global-market-report

Browse Through More Reports Similar to the Global PD-L1 And PIK3CA Testing Market 2026, By The Business Research Company

Hpv Testing And Pap Test Market Report 2026

https://www.thebusinessresearchcompany.com/report/hpv-testing-and-pap-test-global-market-report

D Dimer Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/d-dimer-testing-global-market-report

Direct To Consumer Dtc Laboratory Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/direct-to-consumer-dtc-laboratory-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795